| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. | 2012 | Harv Health Lett | pmid:23243689 | |
| Gonçalves A et al. | [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. | 2012 | Bull Cancer | pmid:23247898 |
| Thudium K et al. | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. | 2013 Jan-Feb | MAbs | pmid:23255090 |
| Cho WC and Roukos DH | Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. | 2013 | Expert Rev Anticancer Ther | pmid:23259420 |
| Damodaran S and Olson EM | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. | 2012 | Hosp Pract (1995) | pmid:23299030 |
| Noguchi E and Shimizu C | [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. | 2013 | Gan To Kagaku Ryoho | pmid:23306913 |
| Faião-Flores F et al. | Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. | 2013 | Tumour Biol. | pmid:23341182 |
| Ludueña RF et al. | Effect of phomopsin A on the alkylation of tubulin. | 1990 | Biochem. Pharmacol. | pmid:2337418 |
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Boyraz B et al. | Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | 2013 | Curr Med Res Opin | pmid:23402224 |
| Carol H et al. | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. | 2013 | Clin. Cancer Res. | pmid:23426279 |
| Dagger F et al. | Regulatory volume decrease in Leishmania mexicana: effect of anti-microtubule drugs. | 2013 | Mem. Inst. Oswaldo Cruz | pmid:23440120 |
| Janthur WD et al. | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. | 2012 | Int J Mol Sci | pmid:23443108 |
| Peddi PF and Hurvitz SA | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. | 2013 | Future Oncol | pmid:23469968 |
| Chu YW and Polson A | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. | 2013 | Future Oncol | pmid:23469971 |
| Dirix LY et al. | Trastuzumab emtansine in breast cancer. | 2013 | Expert Opin Biol Ther | pmid:23477731 |
| Traynor K | Ado-trastuzumab emtansine approved for advanced breast cancer. | 2013 | Am J Health Syst Pharm | pmid:23515502 |
| Zolot RS et al. | Antibody-drug conjugates. | 2013 | Nat Rev Drug Discov | pmid:23535930 |
| Lu D et al. | An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. | 2013 | Clin Pharmacokinet | pmid:23553425 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |